Perioperative immunotherapy for bladder cancer cells

.ANALYSIS HIGHLIGHT.16 Oct 2024.

In the NIAGARA trial, the add-on of perioperative durvalumab to standard procedure for muscle-invasive sac cancer cells boosted event-free and overall survival, noting a brand-new therapy option for this problem.

Articles You Can Be Interested In

• Nutrition
• Self-Help
• Cryptocurrency
• Data Science
• Management
• Mental Health
• Art & Culture
• Public Policy
• World Sports
• Budgeting
• Quantum Computing
• Cultural Events
• Pharmaceuticals
• Philosophy
• Investment
• Social Media
• Cultural Events
• Retail
• Charity
• Tech Updates